Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.
Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.
Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Kelly Benning as Senior Vice President of Truvaga, effective July 21, 2025. Benning brings nearly 30 years of leadership experience in digital health, AI technologies, and consumer wellness.
Benning's impressive background includes pioneering the first FDA-cleared blood pressure monitoring watch and holding executive positions at LiveMetric, IBM Watson Health, CipherHealth, and other healthcare companies. In her new role, she will lead electroCore's consumer wellness division, focusing on strategic partnerships and expanding access to consumer devices through the company's digital wellness platform, Truvaga.
[ "Appointment of experienced executive with nearly 30 years in digital health and AI technologies", "Strategic focus on expanding direct-to-consumer market access", "Addition of leader with proven track record in FDA-cleared medical device commercialization" ]electroCore (NASDAQ: ECOR) reported strong Q2 2025 financial results with record revenue of $7.4 million, representing a 20% year-over-year increase. The company's year-to-date revenue reached $14.1 million, up 22% compared to the first half of 2024.
Key financial metrics include gross profit of $6.4 million with an 87% margin, though operating expenses increased to $9.9 million. The company reported a GAAP net loss of $3.7 million ($0.44 per share). Cash position stood at $7.4 million as of June 30, 2025, supplemented by a recent $7.2 million term debt facility.
electroCore projects full-year 2025 revenue of approximately $30.0 million with expected net cash usage between $3.9-$4.4 million for the remainder of the year. The company successfully completed the NeuroMetrix acquisition ahead of schedule.
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has appointed James C. Theofilos to its Board of Directors, effective August 1, 2025.
Theofilos currently serves as Senior Finance Manager in Microsoft's Azure and AI division, leading finance for the AI Apps & Agents team. His experience includes roles as Finance Lead for Microsoft's Global Healthcare & Life Sciences Sales team and as Group Project Manager at VICI Properties. The Theofilos family has been an early investor and founding partner of electroCore, demonstrating long-term commitment to the company's vision in vagus nerve technology.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has scheduled its Q2 2025 financial results announcement for Wednesday, August 6, 2025, after market close.
The company will host an interactive webinar at 4:30 PM EDT where management will review financial results and take questions from participants. Investors can join using the dial-in number (646) 931-3860, with Webinar ID 843 8084 9004 and Passcode 049555.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in two upcoming investor conferences in August 2025.
The company will attend the Needham 10th Annual Virtual MedTech and Diagnostics Conference on August 11-12, 2025, offering one-on-one meetings. Additionally, management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12 at 3:30 p.m. ET, also providing one-on-one meeting opportunities during the event.
electroCore (NASDAQ: ECOR) reported strong Q1 2025 financial results with net sales of $6.7 million, representing a 23% increase from Q1 2024. The company's core revenue excluding TAC-STIM grew by 29% year-over-year to $6.6 million. Key growth drivers included higher sales of prescription gammaCore™ in the VA market, international market expansion, and strong performance of Truvaga™ wellness products.
The company maintained a robust gross margin of 85%. However, operating expenses increased to $9.5 million, resulting in a GAAP net loss of $3.9 million ($0.47 per share). The quarter included $665,000 in seasonal and non-recurring expenses related to Form 10-K filing, severance, and the NeuroMetrix acquisition.
electroCore provided full-year 2025 guidance of approximately $30.0 million in total revenue and projects net cash usage of $3.8-4.3 million for the next three quarters. The company closed the quarter with $8.0 million in cash and equivalents.
electroCore (NASDAQ: ECOR) has completed its merger with NeuroMetrix (NASDAQ: NURO), acquiring the Quell® Fibromyalgia Solution platform. The acquisition positions electroCore as a leading player in non-invasive bioelectronic technologies, expanding its portfolio in chronic pain and wellness markets. Under the merger terms, NURO shareholders received $4.49 per share in cash plus one contingent value right (CVR) tied to future Quell business sales milestones and proceeds from DPNCheck business disposition.
The strategic acquisition is expected to leverage electroCore's established distribution channels, particularly within the VA Hospital System, to accelerate Quell Fibromyalgia solution adoption. Following the merger completion, NeuroMetrix became an indirect wholly-owned subsidiary of electroCore, with NURO shares being delisted from Nasdaq on May 2, 2025.
electroCore (NASDAQ: ECOR) has announced that its wellness product Truvaga Plus, a hand-held vagus nerve stimulator, is now compatible with the Apple Health app. The integration allows users to track their mental wellbeing data alongside other health metrics in one consolidated platform.
Through the State of Mind API, users can log and monitor their emotional state after each Truvaga Plus session within the Health app's Mental Wellbeing category. Truvaga Plus is designed to provide stress relief, improve sleep, enhance peace of mind, and boost focus through gentle vagus nerve activation.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025, after market close.
The company will host a webinar at 4:30 PM EST where management will review financial results and conduct a Q&A session. Investors interested in participating can access the webinar through:
- Dial-In Number: (646) 931-3860
- Webinar ID: 885 4355 1292
- Passcode: 419231
A registration link is provided for those who wish to participate and ask questions during the call.
electroCore (Nasdaq: ECOR) announced new data demonstrating the effectiveness of gammaCore non-invasive vagus nerve stimulation (nVNS) in treating concussion symptoms from mild traumatic brain injury (mTBI). The study, presented at the 2025 International Brain Injury Association World Congress, involved 102 patients and showed significant improvements in 22 out of 27 measured concussive symptoms.
Key findings revealed notable improvements in post-traumatic headache, nausea, dizziness, and depression. Importantly, the treatment showed similar effectiveness regardless of injury timing, benefiting both recent cases (under three months) and older injuries (over three years), suggesting neuromodulation's potential as a long-term treatment option.
FAQ
What is the current stock price of Electrocore (ECOR)?
What is the market cap of Electrocore (ECOR)?
